Novel genetic analysis in Behçet's disease by Wallace, Graham
Available online http://arthritis-research.com/content/11/4/123
Page 1 of 2
(page number not for citation purposes)
Abstract
Behçet’s disease (BD) is characterized by oral and genital ulcera-
tion and is complicated by eye, skin, joint and central nervous
system lesions. It has long been understood that BD has a strong
genetic component, but to date the identified genes account for
only around 30% of the risk for developing the disease, and the
work has mostly been based on candidate gene analysis. In a
recent report, Fei and coworkers presented the results of the first
genome-wide analysis of patients with BD. These findings suggest
new pathways for investigation in this complex disease.
Error, like straws, upon the surface flow
He who would search for pearls must dive below
John Dryden, 1678
Fei and coworkers [1] identified novel single nucleotide
polymorphisms (SNPs) in five genes (KIAA1529,  CPVL,
LOC100129342,  UBASH3B and  UBAC2) that encode
proteins with both known and unknown functions. Moreover,
subset analysis showed links between some of the SNPs and
particular manifestations of Behçet’s disease (BD).
KIAA1529 and  LOC100129342 have no known function,
but the latter SNP on chromosome 1p34 confirms a locus
previously identified in a multiplex family study [2]. UBASH3B
and  UBAC2 encode ubiquitin-associated proteins. The
ubiquitin system is best described in targeting misfolded or
damaged proteins for proteosomal degradation, but it is also
involved in several other cellular processes, including
regulation of nuclear factor-κB function and autophagy. Such
processes are involved in cells of both innate and adaptive
immune responses, which is of interest with respect to the
ongoing debate on whether BD is an autoinflammatory or an
autoimmune disorder [3]. Dysfunction of the ubiquitin
pathway has been implicated in cancer, neurodegenerative
diseases and type 2 diabetes [4,5].
Carboxypeptidase vitellogenic-like protein is upregulated in
monocytes on conversion to macrophages, in which it co-
localizes to the secreted proteins tumour necrosis factor and
the chemokine CCL3 (C-C chemokine ligand 3). It has been
implicated in the processing/transport of peptides for loading
onto major histocompatibility complex (MHC) class I
molecules [6]. The strongest genetic association with BD is
human leucocyte antigen (HLA)-B*5101 and HLA-B*5108,
an MHC class I molecule. Microsatellite analysis confirms
HLA-B85101/5108 as the most likely causative gene in BD,
but SNPs in other genes in close proximity on chromosome 6 -
MICA, MICB and TNF - have also been reported [7]. More-
over, the mechanism of action of HLA-B*5101/5108 in BD
has not been elucidated. Alteration in the process of peptide
production by the CVLP SNP could have important implica-
tions in the expression or maintenance of MHC class I
molecules on the cell surface and be linked to the patho-
genesis of the disease.
In subset analysis the UBASH3B SNP was more common in
patients with ocular and vascular manifestations, whereas the
KIAA1529 SNP was more common in patients without such
involvement. The authors correctly stated that the numbers
with each manifestation make such an analysis very pre-
liminary, but several other SNPs have been linked to ocular
disease specifically, so these findings are not unexpected [8].
It should be noted, however, that eye and vascular disease
can take many forms in BD, and more detailed analysis will be
required when greater numbers are tested for these SNPs.
There are certain caveats to the findings. Genome-wide
analysis (GWAS) is normally performed on a large number of
samples, which is not easy for a rare condition such as BD.
The authors addressed this point by performing the initial
analysis on pooled samples and then, having identified
potential SNPs, validating the findings in each sample
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individually. However, it is important for these results to be
validated in other cohorts of BD patients. There are extensive
data describing ethnic differences in SNPs studied by
candidate analysis, and the association of these newly
identified SNPs in BD patients from different geographical
areas will be important. Similarly, in several studies males
have been shown to have a worse prognosis, and the
association of these SNPs with sex should be examined.
Other GWAS are ongoing or planned in Japanese, European
and Turkish patients with BD, and comparison with the
current study will be of great interest. Finally, and most impor-
tantly, the functional relevance of these SNPs will need to be
investigated and - if found - tested in different cell types such
as lymphoid, myeloid, epithelial and endothelial cells that are
involved in BD.
BD is a complex disease. Different patients will experience
different symptoms, and there is a clear geographical
distribution of the disease. The candidate gene approach has
been useful in identifying susceptibility and severity genes in
BD, but the ability to undertake GWAS has led to the
identification of several new SNPs in many human diseases,
increasing our understanding of the pathogenic mechanisms
involved. Fei and coworkers [1] are to be commended for
such a study in BD.
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